(For treatment side effects and complications only)
Afatinib Non Small Cell Lung Cancer Protocol V1.1
Alectinib Protocol V1.1
Brigatinib Non-Small Cell Lung Cancer Protocol V1.2
Ceritinib Non Small Cell Lung Cancer Protocol V2.1
Dacomitinib EGFR +ve Non-Small Cell Lung Cancer (NSCLC) Protocol V1.1
Erlotinib Non Small Cell Lung Cancer Protocol V1.1
Gefitinib Non Small Cell Lung Cancer Protocol V1.1
Lorlatinib Protocol V1.0
Osimertinib Adjuvant Use NSCLC EGFR exon 19 deletion or an exon 21 (L858R) Substitution Mutation Protocol V1.1
Tepotinib Advanced NSCLC with MET exon 14 skipping alterations V1.0
Sotorasib KRAS mutated Advanced or Metastatic NSCLC V1.2
Selpercatinib Ret Fusion-Positive Carcinoma V1.0